Novartis Q2 2024. Novartis ag ( nvs) reported that its second quarter net income was $2.32 billion, an increase of about 37% from last year, reflecting higher operating income. Price as of april 26, 2024, 4:00 p.m.
Novartis, maker of blood cancer medicine kymriah, reported core net income from continuing operations of about $3.10 billion, or $1.34 per share, up from $2.74. Novartis last announced its earnings data on january 30th, 2024.
Q2 Sales Accelerate From Slow Start To Year.
Price as of april 25, 2024, 4:00 p.m.
Core Net Profit Easily Beats Market Expectations.
Novartis executives touted strong sales across major brands on an analyst call on tuesday.
The Reported $1.53 Eps For The Quarter, Missing Analysts' Consensus Estimates Of $1.64 By $0.11.
Images References :
Novartis Ag ( Nvs) Reported That Its Second Quarter Net Income Was $2.32 Billion, An Increase Of About 37% From Last Year, Reflecting Higher Operating Income.
Check out novartis india q2 result news, novartis india q2 earnings result updates and highlights.
In Response To Recent Fda Guidelines Which Limit The Nitrosamine Content Of Drugs, Novartis Has Paused.
Surgical sales posted the only increase in q2, rising 7.7% $156 million due to solid myosure and fluent fluid management performance.
So This Is Obviously Data We'll Be Presenting Later This Year At An Upcoming Medical Congress With A Submission Plan In 2024 And A Significant Medicine, We Think,.